Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash-to-Debt 0.19
ELGX's Cash-to-Debt is ranked lower than
87% of the 197 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.55 vs. ELGX: 0.19 )
Ranked among companies with meaningful Cash-to-Debt only.
ELGX' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.19  Med: No Debt Max: No Debt
Current: 0.19
Equity-to-Asset 0.28
ELGX's Equity-to-Asset is ranked lower than
87% of the 189 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.61 vs. ELGX: 0.28 )
Ranked among companies with meaningful Equity-to-Asset only.
ELGX' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.28  Med: 0.84 Max: 0.96
Current: 0.28
0.28
0.96
Piotroski F-Score: 3
Altman Z-Score: -1.25
Beneish M-Score: -3.06
WACC vs ROIC
5.71%
-30.39%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating Margin % -37.45
ELGX's Operating Margin % is ranked lower than
80% of the 194 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.03 vs. ELGX: -37.45 )
Ranked among companies with meaningful Operating Margin % only.
ELGX' s Operating Margin % Range Over the Past 10 Years
Min: -58.38  Med: -21.37 Max: -4.47
Current: -37.45
-58.38
-4.47
Net Margin % -66.43
ELGX's Net Margin % is ranked lower than
84% of the 194 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.21 vs. ELGX: -66.43 )
Ranked among companies with meaningful Net Margin % only.
ELGX' s Net Margin % Range Over the Past 10 Years
Min: -80.17  Med: -32.34 Max: 15.84
Current: -66.43
-80.17
15.84
ROE % -103.36
ELGX's ROE % is ranked lower than
91% of the 187 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 6.23 vs. ELGX: -103.36 )
Ranked among companies with meaningful ROE % only.
ELGX' s ROE % Range Over the Past 10 Years
Min: -143.15  Med: -35.43 Max: 15.58
Current: -103.36
-143.15
15.58
ROA % -34.19
ELGX's ROA % is ranked lower than
84% of the 197 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.67 vs. ELGX: -34.19 )
Ranked among companies with meaningful ROA % only.
ELGX' s ROA % Range Over the Past 10 Years
Min: -44.79  Med: -19.56 Max: 11.48
Current: -34.19
-44.79
11.48
ROC (Joel Greenblatt) % -203.29
ELGX's ROC (Joel Greenblatt) % is ranked lower than
84% of the 195 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 12.30 vs. ELGX: -203.29 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
ELGX' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -298.49  Med: -106.31 Max: -21.18
Current: -203.29
-298.49
-21.18
3-Year Revenue Growth Rate 4.10
ELGX's 3-Year Revenue Growth Rate is ranked higher than
50% of the 159 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.10 vs. ELGX: 4.10 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
ELGX' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -41.3  Med: 11.85 Max: 68.4
Current: 4.1
-41.3
68.4
3-Year EBITDA Growth Rate 95.30
ELGX's 3-Year EBITDA Growth Rate is ranked higher than
95% of the 133 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.80 vs. ELGX: 95.30 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
ELGX' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -51.1  Med: -0.9 Max: 95.3
Current: 95.3
-51.1
95.3
3-Year EPS without NRI Growth Rate 94.40
ELGX's 3-Year EPS without NRI Growth Rate is ranked higher than
95% of the 131 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.20 vs. ELGX: 94.40 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
ELGX' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -51.6  Med: 5.9 Max: 128.9
Current: 94.4
-51.6
128.9
GuruFocus has detected 5 Warning Signs with Endologix Inc $ELGX.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» ELGX's 30-Y Financials

Financials (Next Earnings Date: 2017-08-04 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Instruments & Equipment » Medical Instruments & Supplies    NAICS: 339112    SIC: 3841
Compare:AMEX:CRHM, NAS:ENTL, NAS:STAA, NAS:PLSE, OTCPK:AMSJF, NAS:ATRS, NAS:UTMD, NAS:MLAB, NAS:LMAT, NAS:DSCI, NAS:CFMS, OTCPK:NNCSF, NAS:SIEN, NAS:ANGO, NAS:IVTY, AMEX:TRXC, NAS:LAKE, NAS:HBIO, AMEX:BVX, OTCPK:MRNTF » details
Traded in other countries:RM1.Germany,
Headquarter Location:USA
Endologix Inc develops, manufactures, markets and sells medical devices for the treatment of aortic disorders. Its products are intended for the treatment of abdominal aortic aneurysms.

Endologix Inc was incorporated in California on March 16, 1992 under the name Cardiovascular Dynamics, Inc. and reincorporated in Delaware in June 1993. The Company develops, manufactures, markets and sells medical devices for the treatment of abdominal aortic aneurysms (AAA). Its main products are intended for the treatment of AAA through minimally-invasive endovascular repair (EVAR) or endovascular sealing ('EVAS'), solution for sealing the aneurysm sac while maintaining blood flow through two blood flow lumens. Once AAA develops, it continues to enlarge and, if left untreated, becomes increasingly susceptible to rupture. The Company's EVAR products consist of: a cobalt chromium alloy stent covered by polytetrafluoroethylene graft material; and an accompanying delivery system. The Company's EVAS product consists of: bilateral covered stents with endobags; a biocompatible polymer injected into the endobags to seal the aneurysm; and a delivery system and polymer dispenser. Its main competitors include: Medtronic, Inc., W.L. Gore Inc., and Cook Medical Products, Inc., and new market entrants, TrvVascular, Inc. and Lombard Medical Technologies. The Company is subject to additional licensing and regulatory requirements relating to safe working conditions, manufacturing practices, environmental protection, fire hazard control, and disposal of hazardous or potentially hazardous substances.

Top Ranked Articles about Endologix Inc

ENDOLOGIX ALERT: J&W Investigates Endologix, Inc.; Long Term Investors Encouraged to Contact the Firm
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of Endologix, Inc. - ELGX
Columbia Wanger Buys LCI Industries, Nasdaq Largest buys by the firm in the 4th quarter
Columbia Wanger (Trades, Portfolio) manages a portfolio composed of 197 stocks with a total value of $7.123 billion. During the fourth quarter the guru bought shares in the following stocks: Read more...
EGLX UPCOMING DEADLINE: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving Endologix, Inc. and a Lead Plaintiff Deadline of March 6, 2017

NEW YORK, March 03, 2017 (GLOBE NEWSWIRE) -- The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the Central District of California on behalf of investors who purchased Endologix, Inc. (NASDAQ:ELGX) securities between August 2, 2016 and November 16, 2016.
Click here to learn about the case: http://www.wongesq.com/pslra/endologix-inc. There is no cost or obligation to you. According to the complaint, defendants made false and/or misleading statements and/or failed to disclose that: (1) Endologix did not have the requisite clinical data for FDA premarket approval of its Nellix EndoVascular Aneurysm Sealing System; and (2) as a result, Endologix’s public statements were materially false and misleading at all relevant times. On November 16, 2016, Endologix announced that the FDA requested two-year follow-up data on patients enrolled in the EVAS-FORWARD IDE study to assess Nellix. On this news, shares of Endologix fell $2.02 per share or over 20% to close at $7.82 per share on November 16, 2016, damaging investors. If you suffered a loss in Endologix you have until March 6, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. To obtain additional information, contact Vincent Wong, Esq. either via email [email protected], by telephone at 212.425.1140, or visit http://www.wongesq.com/pslra/endologix-inc. Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigations involving financial fraud and violations of shareholder rights.  Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Vincent Wong, Esq.
39 East Broadway
Suite 304
New York, NY 10002
Tel. 212.425.1140
Fax. 866.699.3880
E-Mail:[email protected]

Read more...
DEADLINE ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Endologix Inc. (ELGX) and Lead Plaintiff Deadline: March 6, 2017

NEW YORK, March 01, 2017 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against Endologix Inc. (“Endologix” or the “Company”) (NASDAQ:ELGX) and certain of its officers, and is on behalf of a class consisting of all persons or entities who purchased Endologix securities August 2, 2016 through November 16, 2016, both dates inclusive (the “Class Period”). Such investors are advised to join this case by visiting the firm’s site: http://www.bgandg.com/elgx. This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934 (the “Exchange Act”). The Complaint alleges that throughout the Class Period Defendants made false and/or misleading statements and/or failed to disclose that: (1) Endologix did not have the necessary clinical data for FDA premarket approval of its Nellix® EndoVascular Aneurysm Sealing System; and (2) consequently, the Company’s public statements were materially false and misleading at all relevant times. On November 16, 2016, Endologix revealed that the FDA requested the Company to provide them with follow up data for two years for patients enrolled in the EVAS-FORWARD-IDE study to assess Nellix. Following this news, Endologix stock dropped $2.02 per share or over 20% to close at $7.82 per share on November 16, 2016. A class action lawsuit has already been filed. If you wish to review a copy of the Complaint you can visit the firm’s site: http://www.bgandg.com/elgx or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss in Endologix you have until March 6, 2017 to request that the Court appoint you as lead plaintiff.  Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique.  Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients.  In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration.   Attorney advertising. Prior results do not guarantee similar outcomes.
Contact:
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | [email protected]

Read more...

Ratios

vs
industry
vs
history
PB Ratio 4.29
ELGX's PB Ratio is ranked lower than
60% of the 183 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.28 vs. ELGX: 4.29 )
Ranked among companies with meaningful PB Ratio only.
ELGX' s PB Ratio Range Over the Past 10 Years
Min: 1.69  Med: 6 Max: 14.18
Current: 4.29
1.69
14.18
PS Ratio 2.09
ELGX's PS Ratio is ranked higher than
65% of the 189 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.25 vs. ELGX: 2.09 )
Ranked among companies with meaningful PS Ratio only.
ELGX' s PS Ratio Range Over the Past 10 Years
Min: 1.14  Med: 5.88 Max: 13.81
Current: 2.09
1.14
13.81
Current Ratio 2.80
ELGX's Current Ratio is ranked higher than
55% of the 194 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.67 vs. ELGX: 2.80 )
Ranked among companies with meaningful Current Ratio only.
ELGX' s Current Ratio Range Over the Past 10 Years
Min: 2.15  Med: 5.75 Max: 20.25
Current: 2.8
2.15
20.25
Quick Ratio 1.74
ELGX's Quick Ratio is ranked higher than
51% of the 194 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.73 vs. ELGX: 1.74 )
Ranked among companies with meaningful Quick Ratio only.
ELGX' s Quick Ratio Range Over the Past 10 Years
Min: 1.74  Med: 4.58 Max: 19.04
Current: 1.74
1.74
19.04
Days Inventory 226.06
ELGX's Days Inventory is ranked lower than
81% of the 183 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 128.19 vs. ELGX: 226.06 )
Ranked among companies with meaningful Days Inventory only.
ELGX' s Days Inventory Range Over the Past 10 Years
Min: 168.66  Med: 215.97 Max: 301.48
Current: 226.06
168.66
301.48
Days Sales Outstanding 57.41
ELGX's Days Sales Outstanding is ranked higher than
55% of the 161 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 61.12 vs. ELGX: 57.41 )
Ranked among companies with meaningful Days Sales Outstanding only.
ELGX' s Days Sales Outstanding Range Over the Past 10 Years
Min: 57.41  Med: 65.71 Max: 77.86
Current: 57.41
57.41
77.86
Days Payable 51.08
ELGX's Days Payable is ranked higher than
52% of the 152 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 50.69 vs. ELGX: 51.08 )
Ranked among companies with meaningful Days Payable only.
ELGX' s Days Payable Range Over the Past 10 Years
Min: 51.08  Med: 109.95 Max: 189.92
Current: 51.08
51.08
189.92

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -9.00
ELGX's 3-Year Average Share Buyback Ratio is ranked lower than
63% of the 131 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: -4.20 vs. ELGX: -9.00 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
ELGX' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -35.1  Med: -9.85 Max: -2.8
Current: -9
-35.1
-2.8

Valuation & Return

vs
industry
vs
history
Price-to-Median-PS-Value 0.36
ELGX's Price-to-Median-PS-Value is ranked higher than
91% of the 174 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.12 vs. ELGX: 0.36 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
ELGX' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.23  Med: 1.15 Max: 8.67
Current: 0.36
0.23
8.67
Earnings Yield (Greenblatt) % -20.14
ELGX's Earnings Yield (Greenblatt) % is ranked lower than
89% of the 197 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.66 vs. ELGX: -20.14 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
ELGX' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -29.9  Med: -4.8 Max: -0.5
Current: -20.14
-29.9
-0.5

More Statistics

Revenue (TTM) (Mil) $193.17
EPS (TTM) $ -1.55
Beta0.39
Short Percentage of Float26.16%
52-Week Range $4.21 - 14.50
Shares Outstanding (Mil)82.98

Analyst Estimate

Dec17 Dec18
Revenue (Mil $) 194 208
EPS ($) -0.72 -0.55
EPS without NRI ($) -0.72 -0.55
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for ELGX

Headlines

Articles On GuruFocus.com
ENDOLOGIX ALERT: J&W Investigates Endologix, Inc.; Long Term Investors Encouraged to Contact the Fir Jun 13 2017 
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Concerning Possible Breaches of May 01 2017 
Columbia Wanger Buys LCI Industries, Nasdaq Mar 09 2017 
EGLX UPCOMING DEADLINE: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involvin Mar 03 2017 
DEADLINE ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Endolo Mar 01 2017 
Meridian Growth Fund 4th Quarter Commentary Feb 21 2017 
Meridian Funds Comments on Endologix Inc Dec 17 2014 
Meridian Contrarian Fund 3Q 2014 Commentary Dec 17 2014 
Weekly CFO Sells Highlight: ELGX, LOW, NWS, SBUX, WLP Dec 18 2012 
Endologix Inc Reports Operating Results (10-K) Mar 16 2011 

More From Other Websites
ENDOLOGIX ALERT: J&W Investigates Endologix, Inc.; Long Term Investors Encouraged to Contact the... Jun 13 2017
Robbins Arroyo LLP: Endologix, Inc. (ELGX) Misled Shareholders According to a Recently Filed Class... Jun 12 2017
Endologix Presents Positive Two-Year Clinical Data from the Nellix® EVAS FORWARD IDE Trial Jun 03 2017
Endologix Reports Positive Clinical Data from the Ovation LUCY Study with 1.3% Major Adverse Event Jun 01 2017
Endologix Reports Positive Clinical Data from the Ovation LUCY Study May 31 2017
ETFs with exposure to Endologix, Inc. : May 26, 2017 May 26 2017
INVESTOR ALERT: Levi & Korsinsky, LLP Announces an Investigation Concerning Possible Breaches of... May 26 2017
Today's Research Reports on Stocks to Watch: GlycoMimetics and Endologix May 19 2017
Why Endologix Shares Are Hitting a Multiyear Low May 18 2017
Why Endologix, Inc. Is Getting Crushed Today May 18 2017
Endologix Provides an Update on the Nellix® Endovascular Aneurysm Sealing System U.S. Regulatory... May 17 2017
Endologix, Inc. breached its 50 day moving average in a Bearish Manner : ELGX-US : May 16, 2017 May 16 2017
Edited Transcript of ELGX earnings conference call or presentation 4-May-17 8:30pm GMT May 10 2017
Endologix, Inc. :ELGX-US: Earnings Analysis: Q1, 2017 By the Numbers : May 9, 2017 May 09 2017
Endologix reports 1Q loss May 04 2017
Endologix Reports First Quarter 2017 Financial Results May 04 2017
Implied Volatility Surging for Endologix (ELGX) Stock Options May 02 2017
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Concerning Possible Breaches of... May 01 2017
Endologix, Inc. to Host an Investor Conference Call to Discuss its Nellix® Endovascular Aneurysm... Apr 24 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}